Advocating for the Laboratory Profession - Insights
In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton. Their...
Is the term "outreach" obsolete? - Insights
In a competitive outpatient testing market, choosing a laboratory is discretionary. With the goal of becoming the laboratory of choice for discretionary outpatient testing, it no longer matters if it is called “inreach” or “outreach.” While...
How the COVID-19 pandemic has increased public knowledge of lab testing - Insights
While the accelerated innovation and increased access to testing that’s occurred because of the COVID-19 pandemic has been critically important to worldwide health care, so too has the crash course in laboratory testing and pathology the...
In this month's "Hot Topic," Brad Karon, M.D., Ph.D., reviews pediatric venipuncture volumes in this year’s Phlebotomy Top Gun case-based presentation as requested by previous Phlebotomy conference attendees.
MCL @Work: Wendy Sempf - Insights
Wendy is a clinical laboratory technologist who works in the Hematopathology Morphology Laboratory at Mayo Clinic Laboratories. Although she’s worked with Mayo Clinic since 1989, her greatest passion is serving others throughout the...
Building Blocks for a Successful Contact Center - Insights
Skip to Content MayoACCESS MayoLINK...
Test panel guides diagnosis of early onset IBD: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy...
Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. - Insights
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal...
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. - Insights
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and...
Test helps identify elusive central nervous system pathogens: Robin Patel, M.D. - Insights
Robin Patel, M.D., explains how a new Mayo Clinic Laboratories' assay can identify central nervous system pathogens that standard tests fail to detect. Rapid, precise diagnosis is essential to preventing long-term effects from these...